Literature DB >> 2859931

Beneficial effects of high-dose diltiazem in patients with persistent effort angina on beta-blockers and nitrates: a randomized, double-blind, placebo-controlled cross-over study.

W E Boden, E W Bough, M J Reichman, V B Rich, P M Young, K S Korr, R S Shulman.   

Abstract

The effects of orally administered diltiazem combined with maximally tolerated doses of beta-blockers and nitrates were assessed in 12 patients, who during stress testing exhibited persistent effort angina and continued objective evidence for inducible myocardial ischemia. Patients performed multistage semisupine exercise on a bicycle ergometer during equilibrium-gated radionuclide angiography after consecutive 2 week treatment periods of placebo or diltiazem 90 mg qid (mean dose 340 mg/day) combined with maximally tolerated propranolol (mean dose 178 mg/day) and isosorbide dinitrate (mean dose 137 mg/day). All medications (including diltiazem or placebo) were administered four times daily for the duration of the study. Diltiazem or placebo was administered according to a double-blind design, with randomized cross-over at the end of each 2 week treatment period. The average number of angina attacks decreased during the double-blind cross-over phase of the trial (7 +/- 7 episodes/week at baseline vs 4 +/- 3 on placebo vs 2 +/- 2 on diltiazem; p = .08). Angina pectoris was abolished during peak exercise in eight of 12 patients on diltiazem (p less than .05 vs placebo). Diltiazem increased total exercise duration from 276 +/- 92 to 310 +/- 78 sec (p less than .005 vs baseline). Diltiazem likewise increased the time to onset of angina from 231 +/- 84 sec at baseline to 305 +/- 77 sec (p less than .005), as well as the time to the onset of 1 mm ischemic ST segment depression (p = .01). Diltiazem decreased heart rate at rest, during submaximal workload, and at peak exercise (p less than .05), and decreased systolic blood pressure at peak exercise only (p less than .05). A significant decline in rate-pressure product at submaximal and peak exercise was noted (p less than .05). At any given workload there was significantly less ST segment depression during submaximal (p = .05) and peak exercise (p less than .025).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859931     DOI: 10.1161/01.cir.71.6.1197

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  11 in total

Review 1.  Beta-adrenoceptor partial agonists: a renaissance in cardiovascular therapy?

Authors:  D G Waller
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

Review 2.  Calcium channel antagonism and beta blockade in combination--a therapeutic alternative in cardiovascular disorders. A review.

Authors:  J N Lessem; B N Singh
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

3.  The efficacy and tolerance to three doses of diltiazem in elderly patients with stable angina.

Authors:  R L Logan
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 4.  Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Authors:  M M Buckley; S M Grant; K L Goa; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 5.  Combination and triple therapy in patients with stable angina pectoris not adequately controlled by optimal β-blocker therapy.

Authors:  W E M Kok; F C Visser; C A Visser
Journal:  Neth Heart J       Date:  2002-11       Impact factor: 2.380

Review 6.  Combination of nitrates with other antianginal drugs.

Authors:  K E Andersson; P Hoglund
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 7.  Diltiazem. A review of its pharmacology and therapeutic use in older patients.

Authors:  A Markham; R N Brogden
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

8.  Interactions of a new beta-blocker, celiprolol, with the calcium antagonists, diltiazem and nifedipine, on atrioventricular conduction.

Authors:  S Motomura; K Hashimoto
Journal:  Cardiovasc Drugs Ther       Date:  1995-06       Impact factor: 3.727

9.  The evolving role of medical therapy for chronic stable angina.

Authors:  Freidy Eid; William E Boden
Journal:  Curr Cardiol Rep       Date:  2008-07       Impact factor: 2.931

10.  Myocardial cell membrane stress ionic dyskinesia reversal by diltiazem.

Authors:  Om Gomes; Es Gomes
Journal:  Exp Clin Cardiol       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.